Group
anti-GD2 mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Mechanism of Action | Anti-GD2 antibody |
| Drugs in group | Dinutuximab· Naxitamab |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Immunologically synergistic (RT-enhanced ADCC), not a DNA-level sensitizer (Cash et al., Journal of Clinical Oncology, 2025; Anderson et al., Clinical Cancer Research, 2022). The principal class adverse event is severe neuropathic pain and capillary-leak/hypersensitivity from the antibody itself; theoretical overlap of RT-induced inflammation with antibody-mediated inflammation could aggravate local reactions.
The data above refer to patients treated with anti-GD2 mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.